ENPP2 and cardiovascular disorder: Recently, many studies have shown that inhibiting ATX can have a promising therapeutic effect on many diseases, such as the growth and metastasis of various tumors such as oral squamous cell carcinoma (OSCC) [31] and breast cancer [32], peritoneal spread in patients with pancreatic ductal adenocarcinoma (PDAC) [33], cardiovascular disease [34], fibrosis of organs such as kidney, heart and lung [35,36], and central nervous system disease [37,38].